Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04051775
Other study ID # 2018/938
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2018
Est. completion date June 30, 2023

Study information

Verified date July 2022
Source Haukeland University Hospital
Contact Erik Johnsen, PhD
Phone 0047 55958400
Email erik.johnsen@helse-bergen.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objectives of the project are to investigate feasibility, safety, and health-related outcomes in patients with psychosis who choose not to use antipsychotic drugs (APs). The instruction from the Ministry of Health and Care Services to establish "Medication Free" (non-pharmacological (NonPharm)) treatment services, which has received substantial critique for being given without support in scientific evidence, provides a window of opportunity for research in an under-investigated field. The study will prospectively follow a cohort over 1 year who seeks NonPharm treatment, with repeated measurements of symptoms, functional outcomes, quality of life, adverse events, as well as biological parameters including genetics and brain imaging, and environmental factors, and compare the findings to a control group of users of antipsychotic drugs, matched for age, gender and diagnosis. Current unanswered questions in the treatment of psychosis include which patients can successfully and safely discontinue antipsychotic medication; and what are the long-term symptomatic, biological and functional outcomes after use or non-use of APs, respectively. Taken together there is a fundamental lack of high-quality evidence to guide the treatment options in people who cannot or do not want to use APs in psychosis. This is also a major challenge in the study, as a more rigorous design that could directly compare different treatment options is not feasible, because no alternatives to APs have proven to be sufficiently effective and safe in controlled trials. The study is accordingly expected to provide new exploratory information that could be the basis of intervention studies which in its turn could provide important information for consumers and the mental health services regarding treatment options in psychosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Fulfillment of diagnostic criteria for schizophrenia or related disorder (corresponding to chapter F2 in the ICD-10) - The clinician responsible for the treatment must consider nonpharmacological treatment to be professionally justifiable in the patient in question - Patient being able/ capable of providing informed consent - Patient receiving active treatment including different psychosocial treatments - Patient having a treatment plan and a crisis resolution plan. Exclusion Criteria Not fullfilling inclusion criteria

Study Design


Locations

Country Name City State
Norway Haukeland Univsersity Hospital Bergen

Sponsors (1)

Lead Sponsor Collaborator
Haukeland University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serious adverse events To investigate the prevalence of any Serious Adverse Events (SAE) in the NorPharm group compared to the control group One year
Secondary Time to remission To investigate the time to remission (absence of positive psychotic symptoms as determined by the Positive And Negative Syndrome Scale) One year
Secondary Time to recovery To investigate the time to recovery (absence of positive psychotic symptoms plus normalized functioning) One year
Secondary Time to relapse To investigate the time to relapse (presence of positive psychotic symptoms) One year
Secondary Insight To investigate the change of insight as determined by Beck Cognitive Insight Scale (BCIS) One year
Secondary Insight To investigate the change of insight as determined by Medication Adherence Report Scale One year
Secondary Insight To investigate the change of insight as determined by Birchwood Insight Scale One year